Cargando…

Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand

The severe acute respiratory syndrome 2 (SARS-CoV-2) has spread rapidly worldwide, not only causing significant morbidity and mortality but also dramatically increasing health care spending. To manage this in Thailand, healthcare workers first received two doses of the CoronaVac vaccine followed by...

Descripción completa

Detalles Bibliográficos
Autores principales: Phumisantiphong, Uraporn, Chunhakan, Sirichan, Manomaipiboon, Anan, Maneerit, Jakravoot, Dechanuwong, Pornchai, Trakarnvanich, Thananda, Oajaum, Wadakorn, Chan-in, Wilawan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940472/
https://www.ncbi.nlm.nih.gov/pubmed/36845212
http://dx.doi.org/10.1016/j.jvacx.2023.100277
_version_ 1784891085007355904
author Phumisantiphong, Uraporn
Chunhakan, Sirichan
Manomaipiboon, Anan
Maneerit, Jakravoot
Dechanuwong, Pornchai
Trakarnvanich, Thananda
Oajaum, Wadakorn
Chan-in, Wilawan
author_facet Phumisantiphong, Uraporn
Chunhakan, Sirichan
Manomaipiboon, Anan
Maneerit, Jakravoot
Dechanuwong, Pornchai
Trakarnvanich, Thananda
Oajaum, Wadakorn
Chan-in, Wilawan
author_sort Phumisantiphong, Uraporn
collection PubMed
description The severe acute respiratory syndrome 2 (SARS-CoV-2) has spread rapidly worldwide, not only causing significant morbidity and mortality but also dramatically increasing health care spending. To manage this in Thailand, healthcare workers first received two doses of the CoronaVac vaccine followed by a booster vaccine with either BNT162b2 vaccine (Pfizer-BioNTech; PZ) or ChAdOx1 nCoV-19 vaccine (Oxford–AstraZeneca; AZ). Given that the difference in anti-SARS-CoV-2 levels following vaccination may vary depending on the vaccine and on demographic characteristics, we measured the antibody response after the second CoronaVac dose and after the booster with either the PZ or AZ vaccine. Our results in 473 healthcare workers show that the variation in antibody response to the full CoronaVac dose depends on demographic characteristics such as age, gender, body mass index, and underlying disease. After receiving a booster dose, anti-SARS-CoV-2 levels were significantly higher in participants who received the PZ vaccine than in people who received the AZ vaccine. Overall, however, receiving a booster dose of either the PZ or AZ vaccine promoted strong antibody responses, even in the old and those with obesity or diabetes mellitus. In conclusion, our results support the use of a booster vaccination program after full vaccination with the CoronaVac vaccine. This approach effectively enhances immunity against SARS-CoV-2, especially in clinically vulnerable groups and healthcare workers.
format Online
Article
Text
id pubmed-9940472
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99404722023-02-21 Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand Phumisantiphong, Uraporn Chunhakan, Sirichan Manomaipiboon, Anan Maneerit, Jakravoot Dechanuwong, Pornchai Trakarnvanich, Thananda Oajaum, Wadakorn Chan-in, Wilawan Vaccine X Regular paper The severe acute respiratory syndrome 2 (SARS-CoV-2) has spread rapidly worldwide, not only causing significant morbidity and mortality but also dramatically increasing health care spending. To manage this in Thailand, healthcare workers first received two doses of the CoronaVac vaccine followed by a booster vaccine with either BNT162b2 vaccine (Pfizer-BioNTech; PZ) or ChAdOx1 nCoV-19 vaccine (Oxford–AstraZeneca; AZ). Given that the difference in anti-SARS-CoV-2 levels following vaccination may vary depending on the vaccine and on demographic characteristics, we measured the antibody response after the second CoronaVac dose and after the booster with either the PZ or AZ vaccine. Our results in 473 healthcare workers show that the variation in antibody response to the full CoronaVac dose depends on demographic characteristics such as age, gender, body mass index, and underlying disease. After receiving a booster dose, anti-SARS-CoV-2 levels were significantly higher in participants who received the PZ vaccine than in people who received the AZ vaccine. Overall, however, receiving a booster dose of either the PZ or AZ vaccine promoted strong antibody responses, even in the old and those with obesity or diabetes mellitus. In conclusion, our results support the use of a booster vaccination program after full vaccination with the CoronaVac vaccine. This approach effectively enhances immunity against SARS-CoV-2, especially in clinically vulnerable groups and healthcare workers. Elsevier 2023-02-20 /pmc/articles/PMC9940472/ /pubmed/36845212 http://dx.doi.org/10.1016/j.jvacx.2023.100277 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Regular paper
Phumisantiphong, Uraporn
Chunhakan, Sirichan
Manomaipiboon, Anan
Maneerit, Jakravoot
Dechanuwong, Pornchai
Trakarnvanich, Thananda
Oajaum, Wadakorn
Chan-in, Wilawan
Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand
title Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand
title_full Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand
title_fullStr Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand
title_full_unstemmed Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand
title_short Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand
title_sort comparison of antibody responses before and after booster doses with the pfizer-biontech or oxford–astrazeneca vaccines in healthcare workers in thailand
topic Regular paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940472/
https://www.ncbi.nlm.nih.gov/pubmed/36845212
http://dx.doi.org/10.1016/j.jvacx.2023.100277
work_keys_str_mv AT phumisantiphonguraporn comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand
AT chunhakansirichan comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand
AT manomaipiboonanan comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand
AT maneeritjakravoot comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand
AT dechanuwongpornchai comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand
AT trakarnvanichthananda comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand
AT oajaumwadakorn comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand
AT chaninwilawan comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand